This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (21)  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in JAMA  Topic Collections  • Medical Practice  • Health Policy  • Quality of Care  • Quality of Care, Other  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Brian L. Strom, MD, MPH

JAMA. 2006;295:2072-2075.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

If the whole materia medica, as now used, could be sunk to the bottom of the sea, it would be all the better for mankind, and all the worse for the fishes.—Oliver Wendell Holmes, Sr¹

Author Affiliation: Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Drug Safety Monitoring
Bruce Ruck, Steven Marcus, John Kashani, and Zdravko Vassilev
JAMA. 2006;296(13):1590.
EXTRACT | FULL TEXT  

Drug Safety Monitoring—Reply
Brian L. Strom
JAMA. 2006;296(13):1590.
EXTRACT | FULL TEXT  

Sweeping Changes to Food and Drug Administration and Drug Safety Regulations
James T. Cross
Arch Intern Med. 2007;167(7):732.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

On the importance of heterogeneity in meta-analysis
Keefe and Strom
Clin Trials 2009;6:443-444.
 

Evaluation of adverse drug reactions reported to a poison control center between 2000 and 2007
Vassilev et al.
Am J Health Syst Pharm 2009;66:481-487.
ABSTRACT | FULL TEXT  

Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis
Agarwal et al.
Nephrol Dial Transplant 2009;24:856-863.
ABSTRACT | FULL TEXT  

Scientific Evidence Underlying the ACC/AHA Clinical Practice Guidelines
Tricoci et al.
JAMA 2009;301:831-841.
ABSTRACT | FULL TEXT  

The New Food and Drug Administration Drug Package Insert: Implications for Patient Safety and Clinical Care
Watson and Barash
Anesth. Analg. 2009;108:211-218.
ABSTRACT | FULL TEXT  

National Trends in Treatment of Type 2 Diabetes Mellitus, 1994-2007
Alexander et al.
Arch Intern Med 2008;168:2088-2094.
ABSTRACT | FULL TEXT  

Long-Term Results of Rabbit Antithymocyte Globulin and Basiliximab Induction
Brennan and Schnitzler
NEJM 2008;359:1736-1738.
FULL TEXT  

Adverse Event Detection in Drug Development: Recommendations and Obligations Beyond Phase 3
Berlin et al.
AJPH 2008;98:1366-1371.
ABSTRACT | FULL TEXT  

Pulmonary embolism in a patient taking clozapine
Srihari and Lee
BMJ 2008;336:1499-1501.
FULL TEXT  

Ten years of adverse drug reaction reports for the multiple sclerosis immunomodulatory therapies: a Canadian perspective
Tremlett and Oger
Mult Scler 2008;14:94-105.
ABSTRACT  

Erectile dysfunction drugs and risk of anterior ischaemic optic neuropathy: casual or causal association?
Danesh-Meyer and Levin
Br J Ophthalmol 2007;91:1551-1555.
ABSTRACT | FULL TEXT  

Importance and Challenges of Studying Marketed Drugs: What Is a Phase IV Study? Common Clinical Research Designs, Registries, and Self-Reporting Systems
Glasser et al.
J Clin Pharmacol 2007;47:1074-1086.
ABSTRACT | FULL TEXT  

Evaluation of Serious Adverse Drug Reactions: A Proactive Pharmacovigilance Program (RADAR) vs Safety Activities Conducted by the Food and Drug Administration and Pharmaceutical Manufacturers
Bennett et al.
Arch Intern Med 2007;167:1041-1049.
ABSTRACT | FULL TEXT  

Assessing A Structured, Quantitative Health Outcomes Approach To Drug Risk-Benefit Analysis
Garrison et al.
Health Aff (Millwood) 2007;26:684-695.
ABSTRACT | FULL TEXT  

Sweeping Changes to Food and Drug Administration and Drug Safety Regulations
Cross
Arch Intern Med 2007;167:732-732.
FULL TEXT  

The FDA and drug safety: a proposal for sweeping changes.
Furberg et al.
Arch Intern Med 2006;166:1938-1942.
ABSTRACT | FULL TEXT  

Drug Safety Monitoring
Ruck et al.
JAMA 2006;296:1590-1590.
FULL TEXT  

Phase 1 clinical trials: not just for safety anymore?
Khandekar and Khandekar
Arch Intern Med 2006;166:1440-1441.
FULL TEXT  

What Price Pain Relief?
Hochman and Shah
Circulation 2006;113:2868-2870.
FULL TEXT